81_FR_15598 81 FR 15542 - National Cancer Institute; Notice of Closed Meeting

81 FR 15542 - National Cancer Institute; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 56 (March 23, 2016)

Page Range15542-15543
FR Document2016-06479

Federal Register, Volume 81 Issue 56 (Wednesday, March 23, 2016) 
[Federal Register Volume 81, Number 56 (Wednesday, March 23, 2016)]
[Notices]
[Pages 15542-15543]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-06479]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2); notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate requests 
for preclinical development resources for potential new therapeutics 
for the treatment of cancer. The outcome of the evaluation will provide 
information to internal NCI committees that will decide whether NCI 
should support requests and make available contract resources for 
development of the potential therapeutic to improve the treatment of 
various forms of cancer. The research proposals and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material, and personal information concerning individuals 
associated with the proposed research projects, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Feb 2016 Cycle 22 NExT SEP Committee Meeting.
    Date: April 27, 2016.
    Time: 8:30 a.m. to 4:30 p.m.
    Agenda: To evaluate the NCI Experimental Therapeutics Program 
Portfolio.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Campus Building 31,

[[Page 15543]]

Conference Room 6C10, Bethesda, MD 20892 (Telephone Conference 
Call).
    Contact Person: Barbara Mroczkowski, Ph.D., Executive Secretary, 
Discovery Experimental Therapeutics Program, National Cancer 
Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817, 
(301) 496-4291, [email protected].
    Toby Hecht, Ph.D., Executive Secretary, Development Experimental 
Therapeutics Program, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 3W110, Rockville, MD 20850, (240) 276-5683, 
[email protected].

    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: http://deainfo.nci.nih.gov/advisory/fac/fac.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: March 17, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-06479 Filed 3-22-16; 8:45 am]
BILLING CODE 4140-01-P

15542 Federal Register / Vol. 81, No. 56 / Wednesday, March 23, 2016 / Notices information on those who are to Need and Use of Information to accommodate unforeseen delays in respond, including the use of Collection: The purpose of the proposed collecting the remaining information. appropriate automated, electronic, evaluation is to pursue a comprehensive Like all institutes and centers (ICs) of mechanical, or other technological process and outcome assessment of the the NIH, NCI seeks opportunities for collection techniques or other forms of 15-year old Innovative Molecular improving their programs’ utility for the information technology. Analysis Technologies (IMAT) program. broad continuum of researchers, To Submit Comments and For Further While the program consistently offers clinicians and ultimately patients. NCI Information: To obtain a copy of the promising indicators of success, the full Acting Director Douglas Lowy and other data collection plans and instruments, program has not been evaluated since leadership across NCI, as well as the submit comments in writing, or request 2008, and never in as comprehensive a NCI Board of Scientific Advisors, will more information on the proposed manner as has been formulated in the be the primary users of the evaluation project, contact: Anthony Dickherber, current evaluation plan. An outcome results. Findings are primarily intended NCI Center for Strategic Scientific evaluation of the long-standing National for considering the long-term strategy to Initiatives, 31 Center Drive, Rm10A33, Cancer Institute’s (NCI) IMAT program support innovative technology Bethesda, MD 20892 or call non-toll-free presents a rich and unique opportunity development and how to more number 301–547–9980 or Email your likely to serve institutes across the efficiently translate emerging request, including your address to: National Institutes of Health (NIH), and capabilities through such technologies dickherberaj@mail.nih.gov. Formal perhaps other federal agencies, into the promised benefits for cancer requests for additional plans and considering the costs and benefits of research and clinical care. Interviews instruments must be requested in directing resources towards supporting with grantees, program officers, review writing. technology development. An award officers, and other NIH awardees make Comment Due Date: Comments through the NIH Evaluation Set-Aside up a crucial component of the regarding this information collection are program to support this evaluation, for evaluation plan and will largely follow best assured of having their full effect if which NIH-wide relevance is a principle set survey protocols. Specific near-term received within 60 days of the date of element of determining merit for aims include the use of this information this publication. support, is testament to this. The to consider the utility of continued Proposed Collection: Surveys and evaluation serves as an opportunity to investment through existing Interviews to Support an Evaluation of gauge the impact of investments in solicitations and in strategic planning the Innovative Molecular Analysis technology development and also to generally for institute support for Technologies (IMAT) Program (NCI), assess the strengths and weaknesses of innovative technology development. 0925–0720, Expiration Date 5/31/2016— phased innovation award mechanisms. OMB approval is requested for 1 year. EXTENSION, National Cancer Institute Prior approval from OMB allowed for There are no costs to respondents other (NCI), National Institutes of Health extensive surveys and interviews than their time. The total estimated (NIH). already, and this extension is requested annualized burden hours are 233. ESTIMATED ANNUALIZED BURDEN HOURS Average Number of Total annual Number of burden per Form name Type of respondents responses per burden respondents response respondent (in hours) (in hours) Interview—IMAT Grantee ................. IMAT Awardees ................................ 18 1 1 18 Web-based Survey—Technology IMAT Awardees; Other NIH Award- 379 1 30/60 190 Grantees. ees representing comparison group. Interview—Tech End-Users .............. Technology End-Users ..................... 50 1 30/60 25 Totals ......................................... ........................................................... 447 447 ........................ 233 Dated: March 16, 2016. is hereby given of the following The research proposals and the Karla Bailey, meeting. discussions could disclose confidential NCI Project Clearance Liaison. National The meeting will be closed to the trade secrets or commercial property Institutes of Health. public in accordance with the such as patentable material, and [FR Doc. 2016–06477 Filed 3–22–16; 8:45 am] provisions set forth in sections personal information concerning BILLING CODE 4140–01–P 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., individuals associated with the proposed research projects, the as amended. The purpose of this disclosure of which would constitute a meeting is to evaluate requests for DEPARTMENT OF HEALTH AND clearly unwarranted invasion of preclinical development resources for HUMAN SERVICES personal privacy. potential new therapeutics for the treatment of cancer. The outcome of the Name of Committee: National Cancer jstallworth on DSK7TPTVN1PROD with NOTICES National Institutes of Health Institute Special Emphasis Panel; Feb 2016 evaluation will provide information to Cycle 22 NExT SEP Committee Meeting. National Cancer Institute; Notice of internal NCI committees that will Date: April 27, 2016. Closed Meeting decide whether NCI should support Time: 8:30 a.m. to 4:30 p.m. requests and make available contract Agenda: To evaluate the NCI Experimental Pursuant to section 10(d) of the resources for development of the Therapeutics Program Portfolio. Federal Advisory Committee Act, as potential therapeutic to improve the Place: National Institutes of Health, 9000 amended (5 U.S.C. Appendix 2); notice treatment of various forms of cancer. Rockville Pike, Campus Building 31, VerDate Sep<11>2014 15:26 Mar 22, 2016 Jkt 238001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\23MRN1.SGM 23MRN1

Federal Register / Vol. 81, No. 56 / Wednesday, March 23, 2016 / Notices 15543 Conference Room 6C10, Bethesda, MD 20892 would constitute a clearly unwarranted Scientific Review, National Institutes of (Telephone Conference Call). invasion of personal privacy. Health, 6701 Rockledge Drive, Room 4142, Contact Person: Barbara Mroczkowski, MSC 7850, Bethesda, MD 20892, (301) 435– Ph.D., Executive Secretary, Discovery Name of Committee: National Institute of 1239, guthriep@csr.nih.gov. Experimental Therapeutics Program, Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Time-Sensitive (Catalogue of Federal Domestic Assistance National Cancer Institute, NIH, 31 Center Program Nos. 93.306, Comparative Medicine; Drive, Room 3A44, Bethesda, MD 20817, Obesity Research. Date: April 15, 2016. 93.333, Clinical Research, 93.306, 93.333, (301) 496–4291, mroczkoskib@mail.nih.gov. 93.337, 93.393–93.396, 93.837–93.844, Time: 2:00 p.m. to 3:00 p.m. Toby Hecht, Ph.D., Executive Secretary, 93.846–93.878, 93.892, 93.893, National Agenda: To review and evaluate grant Development Experimental Therapeutics Institutes of Health, HHS) applications. Program, National Cancer Institute, NIH, Place: National Institutes of Health, Two Dated: March 17, 2016. 9609 Medical Center Drive, Room 3W110, Democracy Plaza, 6707 Democracy David Clary, Rockville, MD 20850, (240) 276–5683, Boulevard, Bethesda, MD 20892 (Telephone toby.hecht2@nih.gov. Conference Call). Program Analyst, Office of Federal Advisory In the interest of security, NIH has Contact Person: Michele L. Barnard, Ph.D., Committee Policy. instituted stringent procedures for entrance Scientific Review Officer, Review Branch, [FR Doc. 2016–06478 Filed 3–22–16; 8:45 am] onto the NIH campus. All visitor vehicles, DEA, NIDDK, National Institutes of Health, BILLING CODE 4140–01–P including taxicabs, hotel, and airport shuttles Room 7353, 6707 Democracy Boulevard, will be inspected before being allowed on Bethesda, MD 20892–2542, (301) 594–8898, campus. Visitors will be asked to show one barnardm@extra.niddk.nih.gov. DEPARTMENT OF HEALTH AND form of identification (for example, a (Catalogue of Federal Domestic Assistance government-issued photo ID, driver’s license, HUMAN SERVICES Program Nos. 93.847, Diabetes, or passport) and to state the purpose of their Endocrinology and Metabolic Research; visit. Substance Abuse and Mental Health 93.848, Digestive Diseases and Nutrition Services Administration Information is also available on the Research; 93.849, Kidney Diseases, Urology Institute’s/Center’s home page: http:// and Hematology Research, National Institutes deainfo.nci.nih.gov/advisory/fac/fac.htm, Center for Substance Abuse of Health, HHS) where an agenda and any additional Treatment; Notice of Meeting information for the meeting will be posted Dated: March 17, 2016. when available. David Clary, Pursuant to Public Law 92–463, (Catalogue of Federal Domestic Assistance Program Analyst, Office of Federal Advisory notice is hereby given that the Program Nos. 93.392, Cancer Construction; Committee Policy. Substance Abuse and Mental Health 93.393, Cancer Cause and Prevention [FR Doc. 2016–06481 Filed 3–22–16; 8:45 am] Services Administration’s (SAMHSA’s) Research; 93.394, Cancer Detection and BILLING CODE 4140–01–P Center for Substance Abuse Treatment Diagnosis Research; 93.395, Cancer (CSAT) National Advisory Council will Treatment Research; 93.396, Cancer Biology meet on April 4, 2016, 2:30 p.m.–3:30 Research; 93.397, Cancer Centers Support; DEPARTMENT OF HEALTH AND p.m. (EDT) in a closed teleconference 93.398, Cancer Research Manpower; 93.399, HUMAN SERVICES meeting. Cancer Control, National Institutes of Health, HHS) The meeting will include discussions National Institutes of Health and evaluations of grant applications Dated: March 17, 2016. reviewed by SAMHSA’s Initial Review Melanie J. Gray, Center for Scientific Review; Notice of Groups, and involve an examination of Program Analyst, Office of Federal Advisory Closed Meeting confidential financial and business Committee Policy. Pursuant to section 10(d) of the information as well as personal [FR Doc. 2016–06479 Filed 3–22–16; 8:45 am] Federal Advisory Committee Act, as information concerning the applicants. BILLING CODE 4140–01–P amended (5 U.S.C. App.), notice is Therefore, the meeting will be closed to hereby given of the following meeting. the public as determined by the Acting The meeting will be closed to the SAMHSA Administrator, in accordance DEPARTMENT OF HEALTH AND public in accordance with the with Title 5 U.S.C. 552b(c)(4) and (6). HUMAN SERVICES provisions set forth in sections Meeting information and a roster of 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Council members may be obtained by National Institutes of Health as amended. The grant applications and accessing the SAMHSA Committee Web National Institute of Diabetes and the discussions could disclose site at http://beta.samhsa.gov/about-us/ Digestive and Kidney Diseases; Notice confidential trade secrets or commercial advisory-councils/csat-national- of Closed Meeting property such as patentable material, advisory-council or by contacting the and personal information concerning CSAT National Advisory Council Pursuant to section 10(d) of the individuals associated with the grant Designated Federal Officer; Tracy Goss Federal Advisory Committee Act, as applications, the disclosure of which (see contact information below). amended (5 U.S.C. App.), notice is would constitute a clearly unwarranted Council Name: SAMHSA’s Center for hereby given of the following meeting. invasion of personal privacy. Substance Abuse Treatment, National The meeting will be closed to the Name of Committee: Center for Scientific Advisory Council. public in accordance with the Review Special Emphasis Panel, Cellular and provisions set forth in sections Molecular Neurosciences. Date/Time/Type: April 4, 2016, 2:30 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Date: April 13, 2016. p.m.–3:30 p.m. EDT, Closed. jstallworth on DSK7TPTVN1PROD with NOTICES as amended. The grant applications and Time: 1:00 p.m. to 4:00 p.m. Place: SAMHSA, 5600 Fishers Lane, the discussions could disclose Agenda: To review and evaluate grant Rockville, Maryland 20857. applications. confidential trade secrets or commercial Place: National Institutes of Health, 6701 Contact: Tracy Goss, Designated property such as patentable material, Rockledge Drive, Bethesda, MD 20892, Federal Officer, CSAT National and personal information concerning (Telephone Conference Call). Advisory Council, 5600 Fishers Lane, individuals associated with the grant Contact Person: Peter B. Guthrie, Ph.D., Rockville, Maryland 20857 (mail), applications, the disclosure of which Scientific Review Officer, Center for Telephone: (240) 276–0759, Fax: (240) VerDate Sep<11>2014 15:26 Mar 22, 2016 Jkt 238001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\23MRN1.SGM 23MRN1


Document Created: 2016-03-23 00:03:25
Document Modified: 2016-03-23 00:03:25
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesApril 27, 2016.
FR Citation81 FR 15542 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR